Melanoma & Skin Cancer | Specialty

FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma

May 6th 2021

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

May 5th 2021

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Dr. Rapisuwon on the Potential Utility of Toripalimab in Melanoma Subtypes

May 4th 2021

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor Types

April 30th 2021

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Dr. Davies on Managing Melanoma During the COVID-19 Pandemic

April 28th 2021

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Dr. Rapisuwon on Frontline Immunotherapy Vs Targeted Therapy in Melanoma Subtypes

April 27th 2021

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma

April 27th 2021

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

First Patients Dosed With PVSRIPO, CT-0508, and TH1902 Boosts Hope for Novel Therapies in Melanoma and Other Solid Tumors

April 22nd 2021

The first patient with PD-1/PD-L1–refractory melanoma has been dosed in the phase 2 LUMINOS-102 trial, which will evaluate the safety and efficacy of PVSRIPO alone or in combination with a PD-1/PD-L1 inhibitor in this patient population.

Dr. Rapisuwon on Biologic Differences Between Mucosal and Cutaneous Melanoma

April 20th 2021

Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.

Darovasertib Shows Encouraging Activity in Metastatic Uveal Melanoma

April 19th 2021

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.